Histopathological Spectrum of Renal Cell Carcinoma and Its Correlation With Clinical Presentation, Imaging Findings, and Surgical Outcomes: A Multicenter Retrospective Observational Study

Sujata Pujari; Mishra Jeeban; Hota Datteswar

doi:10.51168/6pnhcb37

Autori

Sujata Pujari Associate Professor, Department of Pathology, Sri Jagannath Medical College & Hospital, Puri, Odisha, India.
Mishra Jeeban Assistant Professor, Department of Uro-Oncology, Acharya Harihara Post Graduate Institute of Cancer, Cuttack, Odisha, India.
Hota Datteswar M.S., MCH, Ex-HOD, Department of Urology, SCB Medical College & Hospital, Odisha, India.

DOI:

https://doi.org/10.51168/6pnhcb37

Cuvinte cheie:

Renal cell carcinoma, Histopathology, Clear cell RCC, Nephrectomy, World Health Organization/International Society of Urological Pathology (WHO/ISUP) grading, Surgical outcomes

Rezumat

Introduction:
To evaluate the histopathological spectrum of renal cell carcinoma (RCC) and correlate histopathological subtypes and tumor characteristics with clinical presentation, imaging findings, pathological stage, and surgical outcomes.

Methods:
This multicenter retrospective observational study included 120 adults with histopathologically confirmed RCC who underwent radical or partial nephrectomy at Jagannath Medical College & Hospital, Puri, and Acharya Harihara Post Graduate Institute of Cancer, Cuttack. Clinical, radiological, operative, and histopathological records were reviewed. Histopathological assessment included tumor subtype, WHO/ISUP grade, pathological stage, and lymphovascular invasion. Associations with clinical, imaging, and postoperative variables were assessed using appropriate statistical tests.

Results:
Clear cell RCC was the predominant subtype (82, 68.3%), followed by papillary RCC (20, 16.7%) and chromophobe RCC (12, 10.0%). Hematuria (51.7%) and flank pain (45.0%) were the most common presentations, while 31.7% of tumors were detected incidentally. Tumor size >7 cm was significantly associated with advanced pathological stage, renal vein invasion, perinephric fat invasion, and enlarged lymph nodes (p<0.05). High WHO/ISUP grade was significantly associated with advanced pathological stage (p<0.001). Postoperative complications occurred in 15.0% of patients and were associated with larger tumor size, high grade, advanced stage, and renal vein invasion. Multivariate analysis identified tumor size >7 cm, high WHO/ISUP grade, stage III–IV disease, and renal vein invasion as significant predictors of postoperative complications.

Conclusion:
Clear cell RCC predominated, while tumor size, grade, stage, and vascular invasion were significantly associated with disease extent and postoperative outcomes.

Recommendation:
Integrated clinicoradiological and histopathological assessment should be considered for risk stratification and perioperative management of RCC.

Biografii autori

Sujata Pujari, Associate Professor, Department of Pathology, Sri Jagannath Medical College & Hospital, Puri, Odisha, India.

is an Associate Professor in the Department of Pathology at Sri Jagannath Medical College & Hospital, Puri, Odisha, India. Her academic and professional work focuses on diagnostic histopathology and pathological evaluation of disease processes.
Mishra Jeeban, Assistant Professor, Department of Uro-Oncology, Acharya Harihara Post Graduate Institute of Cancer, Cuttack, Odisha, India.

is an Assistant Professor in the Department of Uro-Oncology at Acharya Harihar Post Graduate Institute of Cancer, Cuttack, Odisha, India. His professional interests include uro-oncology, urological malignancies, and surgical management of cancer patients.
Hota Datteswar, M.S., MCH, Ex-HOD, Department of Urology, SCB Medical College & Hospital, Odisha, India.

is a senior urological surgeon and former Head of the Department of Urology at SCB Medical College & Hospital, Odisha, India. His professional expertise includes urological surgery and the management of urological diseases.

Referințe

1. Young M, Powles T, et al. Renal cell carcinoma. Lancet. 2024;404(10451):476-491. https://doi.org/10.1016/S0140-6736(24)00917-6

2. Powles T, Albiges L, Bex A, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(8):692-706. https://doi.org/10.1016/j.annonc.2024.05.537

3. Goswami PR, Singh G, Patel T, Dave R. The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates. Cureus. 2024;16(4):e58470. https://doi.org/10.7759/cureus.58470

4. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. Arnhem: EAU; 2025.

5. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. Arnhem: EAU; 2024.

6. Khoury JD, et al. WHO Classification of Urinary and Male Genital Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2022.

7. Moch H, Amin MB, Berney DM, et al. WHO Classification of Urinary and Male Genital Tumours. 5th ed. Lyon: IARC Press; 2022.

8. Cimadamore A, Cheng L, Scarpelli M, et al. Toward the new WHO classification of renal cell tumors: what clinicians need to know. Transl Androl Urol. 2021;10(3):1506-1520. https://doi.org/10.21037/tau-20-1150

9. Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2022;72(6):526-545.

10. Bex A, Albiges L, Ljungberg B, et al. Updated management of localized and advanced renal cell carcinoma. Eur Urol. 2023;84(3):286-301.

11. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: 2023 update. Eur Urol. 2023;84(4):399-410. https://doi.org/10.1016/j.eururo.2022.03.006

12. Capitanio U, Montorsi F. Renal cancer. Lancet. 2021;398:1697-1710.

13. Delahunt B, Cheville JC, Martignoni G, et al. The evolving classification of renal cell neoplasia. Histopathology. 2022;80(1):5-18. https://doi.org/10.1111/his.13200

14. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. 2022;81(2):150-165.

15. Schieda N, et al. WHO 2022 renal cell tumor classification: imaging features and clinical implications. Radiographics. 2025;45(5).